Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H24N2O2S |
Molecular Weight | 356.482 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)CCNC1=CC=C(CO)C2=C1C(=O)C3=C(S2)C=CC=C3
InChI
InChIKey=MFZWMTSUNYWVBU-UHFFFAOYSA-N
InChI=1S/C20H24N2O2S/c1-3-22(4-2)12-11-21-16-10-9-14(13-23)20-18(16)19(24)15-7-5-6-8-17(15)25-20/h5-10,21,23H,3-4,11-13H2,1-2H3
Molecular Formula | C20H24N2O2S |
Molecular Weight | 356.482 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Hycanthone is a thioxanthene derivative of lucanthone with anti-schistosomal activity and potential antineoplastic activity. It was clinically available for the treatment of human schistosomiasis. Anti-helmintic action relies on its ability to inhibit worm monoamine oxidase and cholinesterases. Hycanthone produced immediate side effects such as hepatotoxicity and gastrointestinal disturbances, and was consequently withdrawn. Hycanthone inhibits apurinic endonuclease-1 (APE1) by direct protein binding. Hycanthone was used in the 1980s as antitumor agents, it was pulled out of Phase II trials.
Originator
Sources: https://patents.google.com/patent/US3312598
Curator's Comment: reference retrieved from www.drugfuture.com/chemdata/hycanthone.html
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: UniProtKB: Q71SU7 (Carboxylic ester hydrolase) |
|||
Target ID: GO:0097621 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7229816 |
|||
Target ID: CHEMBL5619 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21935361 |
80.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Hycanthone Approved Usehuman schistosomiasis |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005 Jun |
|
Mefloquine--an aminoalcohol with promising antischistosomal properties in mice. | 2009 |
|
Reduced susceptibility to praziquantel among naturally occurring Kenyan isolates of Schistosoma mansoni. | 2009 Aug 18 |
|
RNA interference in Schistosoma mansoni schistosomula: selectivity, sensitivity and operation for larger-scale screening. | 2010 Oct 19 |
|
Identification of novel p53 pathway activating small-molecule compounds reveals unexpected similarities with known therapeutic agents. | 2010 Sep 27 |
|
Screening of a chemical library reveals novel PXR-activating pharmacologic compounds. | 2015 Jan 5 |
Patents
Sample Use Guides
Human schistosomiasis: single intramuscular dose (3.0, 2.5, 2.0, 1.5, and 1.0 mg/kg body weight).Unresectable pancreatic cancer: hycanthone was administered 60 mg/m2 intravenously within 2 to 4 hr during each day of the 5-day course of infusions during the first and fifth weeks of radiation therapy.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1190369
Hycanthone stimulates motor activity of Schistosoma mansoni at concentrations of 10(-6) to 10(-5) M, and partially blocks the paralytic effects of carbachol and physostigmine.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 17:12:13 GMT 2023
by
admin
on
Fri Dec 15 17:12:13 GMT 2023
|
Record UNII |
2BXX5EVN2A
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C250
Created by
admin on Fri Dec 15 17:12:13 GMT 2023 , Edited by admin on Fri Dec 15 17:12:13 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2BXX5EVN2A
Created by
admin on Fri Dec 15 17:12:13 GMT 2023 , Edited by admin on Fri Dec 15 17:12:13 GMT 2023
|
PRIMARY | |||
|
221-463-7
Created by
admin on Fri Dec 15 17:12:13 GMT 2023 , Edited by admin on Fri Dec 15 17:12:13 GMT 2023
|
PRIMARY | |||
|
1383
Created by
admin on Fri Dec 15 17:12:13 GMT 2023 , Edited by admin on Fri Dec 15 17:12:13 GMT 2023
|
PRIMARY | |||
|
52768
Created by
admin on Fri Dec 15 17:12:13 GMT 2023 , Edited by admin on Fri Dec 15 17:12:13 GMT 2023
|
PRIMARY | |||
|
HYCANTHONE
Created by
admin on Fri Dec 15 17:12:13 GMT 2023 , Edited by admin on Fri Dec 15 17:12:13 GMT 2023
|
PRIMARY | |||
|
DTXSID9023128
Created by
admin on Fri Dec 15 17:12:13 GMT 2023 , Edited by admin on Fri Dec 15 17:12:13 GMT 2023
|
PRIMARY | |||
|
134434
Created by
admin on Fri Dec 15 17:12:13 GMT 2023 , Edited by admin on Fri Dec 15 17:12:13 GMT 2023
|
PRIMARY | |||
|
142982
Created by
admin on Fri Dec 15 17:12:13 GMT 2023 , Edited by admin on Fri Dec 15 17:12:13 GMT 2023
|
PRIMARY | |||
|
100000084172
Created by
admin on Fri Dec 15 17:12:13 GMT 2023 , Edited by admin on Fri Dec 15 17:12:13 GMT 2023
|
PRIMARY | |||
|
2207
Created by
admin on Fri Dec 15 17:12:13 GMT 2023 , Edited by admin on Fri Dec 15 17:12:13 GMT 2023
|
PRIMARY | |||
|
D006826
Created by
admin on Fri Dec 15 17:12:13 GMT 2023 , Edited by admin on Fri Dec 15 17:12:13 GMT 2023
|
PRIMARY | |||
|
3634
Created by
admin on Fri Dec 15 17:12:13 GMT 2023 , Edited by admin on Fri Dec 15 17:12:13 GMT 2023
|
PRIMARY | |||
|
DB14061
Created by
admin on Fri Dec 15 17:12:13 GMT 2023 , Edited by admin on Fri Dec 15 17:12:13 GMT 2023
|
PRIMARY | |||
|
CHEMBL22077
Created by
admin on Fri Dec 15 17:12:13 GMT 2023 , Edited by admin on Fri Dec 15 17:12:13 GMT 2023
|
PRIMARY | |||
|
SUB08057MIG
Created by
admin on Fri Dec 15 17:12:13 GMT 2023 , Edited by admin on Fri Dec 15 17:12:13 GMT 2023
|
PRIMARY | |||
|
m6068
Created by
admin on Fri Dec 15 17:12:13 GMT 2023 , Edited by admin on Fri Dec 15 17:12:13 GMT 2023
|
PRIMARY | Merck Index | ||
|
C550
Created by
admin on Fri Dec 15 17:12:13 GMT 2023 , Edited by admin on Fri Dec 15 17:12:13 GMT 2023
|
PRIMARY | |||
|
3105-97-3
Created by
admin on Fri Dec 15 17:12:13 GMT 2023 , Edited by admin on Fri Dec 15 17:12:13 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |